title: Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
abstract: Evidence for clinically significant radiosensitization by the halogenated pyrimidine 5-iododeoxyuridine (IdUrd) continues to accumulate. In vitro radiosensitization has been demonstrated in human colon tumor cell lines following exposure to 1-10 micrometer. Coadministration of leucovorin (LV) increases radiosensitization, which correlates directly with increased IdUrd DNA incorporation. Clinical data regarding proliferation rates and thymidine kinase levels in tumors versus normal tissues suggest selective incorporation of IdUrd into gastrointestinal tumors may occur. The objectives of this Phase I study were: (a) to assess the feasibility of LV modulation of IdUrd radiosensitization by determining the maximum tolerated dose (MTD) of IdUrd plus LV; and (b) to perform correlative laboratory studies to investigate the potential of IdUrd plus LV to increase radiosensitization in vivo. Seventeen patients with unresectable or recurrent gastrointestinal adenocarcinomas received a 14-day course of continuous i.v. infusion of IdUrd prior to initiation of radiotherapy. Two additional 14-day infusions of IdUrd with LV were given during the course of radiotherapy (60 Gy in 6 weeks). The initial dose of IdUrd was 250 mg/m2/day and was escalated in subsequent patients to 400 and 600 mg/m2/day. The LV dose remained fixed at 250 mg/m2/day. Leukopenia was the dose-limiting toxicity, and 400 mg/m2/day was the MTD for this trial. At the MTD, the mean +/- SD steady-state plasma concentration of IdUrd during the infusion, measured by high-performance liquid chromatography, was 0.66 +/- 0.23 micrometer. There was no significant influence of LV on IdUrd DNA incorporation in peripheral blood granulocytes as measured by high-performance liquid chromatography. Based on toxicity data and correlative laboratory studies, a meaningful increase in radiosensitization would not be achieved with the IdUrd infusion schedule and dose of LV investigated compared with IdUrd alone.
authors.affiliation: Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: McGinn
authors.forename: K A
authors.initials: KA
authors.lastname: Kunugi
authors.forename: K D
authors.initials: KD
authors.lastname: Tutsch
authors.forename: C
authors.initials: C
authors.lastname: Feierabend
authors.forename: D
authors.initials: D
authors.lastname: Alberti
authors.forename: M J
authors.initials: MJ
authors.lastname: Lindstrom
authors.forename: G
authors.initials: G
authors.lastname: Wilding
authors.forename: R Z
authors.initials: RZ
authors.lastname: Arzoomanian
authors.forename: T J
authors.initials: TJ
authors.lastname: Kinsella
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007065:Idoxuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002955:Leucovorin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*
chemical_list: D011838:Radiation-Sensitizing Agents; D007065:Idoxuridine; D002955:Leucovorin